Do mRNA tumour vaccines herald a new revolution in cancer treatment?

The recent trial results of a personalized mRNA tumour vaccine have shown promising signs of a potential revolution in cancer treatment. For decades, chemotherapy was the primary treatment option, but it often came with severe side effects. The advent of the human genome mapping brought about the era of precision medicine, targeting specific genetic mutations in various cancers.

However, tumours continued to evolve and evade treatment through new mutations. Immunotherapy emerged as a game-changer, unleashing the patient's own immune system to attack cancer cells. Checkpoint inhibitors, such as pembrolizumab and nivolumab, transformed the outlook for metastatic melanoma and subsequently targeted other cancer types like lung, kidney, bladder, liver, and head-and-neck cancers.

The most recent development involves personalized mRNA tumour vaccines. The Phase III INTerpath-001 trial evaluated the efficacy of an mRNA vaccine called intismeran autogene (mRNA-4157/V940) in high-risk melanoma patients. The vaccine was combined with pembrolizumab and was shown to improve recurrence-free and distant metastasis-free survival compared to pembrolizumab alone.

This trial marks the first success of a personalized neoantigen-based mRNA therapy in a large, randomized Phase III study. Unlike traditional vaccines, these are therapeutic vaccines, created after a diagnosis to help the immune system recognize and destroy cancer cells. Personalized mRNA vaccines are now being studied in various cancers, and if successful, could transform treatment by routinely involving genomic sequencing, designing a patient-specific vaccine, and administering it alongside immunotherapy to eliminate residual disease.